OR WAIT null SECS
US Bioservices, an independent pharmacy and a part of AmerisourceBergen, announced that 2017 was a record-breaking year for new business wins in three strategic areas-oncology, rare and orphan, and specialty infusion. US Bioservices received access to 28 new products in 2017, including 10 oncology products and three rare and orphan therapies.
US Bioservices’ portfolio offers:
Through comprehensive technology systems, US Bioservices’ manufacturer partners get a transparent view into the therapy experience.
US Bioservices leverages resources provided by AmerisourceBergen companies, including Lash Group for patient support services; ION Solutions and Oncology Support for their connections to community oncology providers, and ICS and ASD Healthcare for rare and orphan logistics and distribution.